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Acute myeloid leukaemia (AML) is a haematological malignancy characterized by clonal stem cell proliferation and aberrant block
in differentiation.Dysfunction of epigeneticmodifiers contributes significantly to the pathogenesis ofAML.One frequentlymutated
gene involved in epigenetic modification is DNMT3A (DNAmethyltransferase-3-alpha), a DNAmethyltransferase that alters gene
expression by de novo methylation of cytosine bases at CpG dinucleotides. Approximately 22% of AML and 36% of cytogenetically
normal AML cases carry DNMT3A mutations and around 60% of these mutations affect the R882 codon. These mutations have
been associated with poor prognosis and adverse survival outcomes for AML patients. Advances in whole-exome sequencing
techniques have recently identified a large number of DNMT3Amutations present in clonal cells in normal elderly individuals with
no features of haematologicalmalignancy. Categorically distinct fromother preleukaemic conditions, this disorder has been termed
clonal haematopoiesis of indeterminate potential (CHIP). Further insight into the mutational landscape of CHIPmay illustrate the
consequence of particularmutations found inDNMT3A and identify specific “founder”mutations responsible for clonal expansion
that may contribute to leukaemogenesis. This review will focus on current research and understanding of DNMT3A mutations in
both AML and CHIP.
1. DNA Methylation
1.1. Epigenetic Modifications. Normal haematopoiesis is one
of many cellular processes regulated by epigenetic modifi-
cation. Haematopoietic stem cells (HSCs) are required to
proliferate, differentiate, and mature in a controlled fashion
down various distinct myeloid and lymphoid lineages giving
rise to terminally differentiated blood cells. Due to the
varied number of lineages that can arise from haematopoietic
stem cells, dysfunction produces an assortment of disease
phenotypes. Aberrant expressions of epigenetic regulators are
increasingly recognised as being central to this process.
Two major forms of epigenetic regulation are recognised.
DNA methylation involves direct modification of the DNA
molecule itself via the addition of a methyl group to cytosine
bases, generally at CpG dinucleotides, without any actual
alteration of the DNA sequence itself, changing how the
DNA is read and influencing the level of expression of the
gene. A second level of epigenetic regulation occurs at the
level of the histones which can undergo various chemical
modifications including methylation, phosphorylation, and
acetylation, thereby influencing local transcriptional activity.
In this report, we discuss DNA methylation and its role in
haematopoiesis and haematological malignancy with partic-
ular focus on DNMT3A.
1.2. DNA Methylation. DNA methylation is an important
process involved in developmental patterning, chromatin
modification, and imprinting. Aberrant methylation has long
been recognised to have a role in disease processes such as
cancer [1, 2]. As Figure 1 shows, methylation involves the
addition of a methyl group (CH3) to specific cytosines base
found in the DNA sequence to produce 5-methylcytosine
(5mC) [3].
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Figure 1: DNA methylation by DNA methyltransferase enzymes. An illustration showing the positively charged histones binding the
negatively charged DNA into compact chromatin to prevent gene transcription. The figure shows how other proteins can interact with
histones to regulate transcription of genes. Modifications of histones tails such as acetylation andmethylation change chromatin architecture,
unwinding chromatin to allow access to the DNA sequence. Several other proteins, including chromatin remodellers, can also affect
chromatin architecture. Regulators such as DNA methyltransferase enzymes are then able to access DNA to add methyl groups (CH3) to
appropriate cytosine bases.Themethyl group is added to the C5 position of the pyrimidine ring to produce 5-methylcytosine (5mC). Aberrant
methylation as illustrated can inactivate tumor suppressor genes (through hypermethylation) and increase expression of oncogenes (through
hypomethylation of promotor sites of these genes), both of which can contribute to leukaemogenesis.
Methylation occurs at sites in the genome where the
cytosine base is bound to the adjacent guanine base by a
phosphodiester bond. These sites are referred to as CpG
residues and human genes have approximately 60–80% of
these individual CpGs methylated [4]. However, clustered
CpG residues in “islands” are often located near gene pro-
moter regions and are predominantly nonmethylated [4].
This allows for important regulation of gene expression.
While highly studied, the purpose and function of theseDNA
methylated promotor sites are not well understood. Previous
studies have highlighted that the density of CpG residues have
been consequently related to methylation levels. Promoter
sites that are poorly populated with CpG residues are seen to
be highly methylated, while the opposite has been observed
in promotor sites with highly populated CpG residues [5].
While studies have suggested a correlation between promoter
methylation and transcriptional activity, with methylated
promoters often being transcriptionally silent [4, 6–9], it is
not clear that DNA methylation itself is responsible for gene
silencing, and rather regulation of gene expression through
DNA methylation may be far more complex.
New methods in genome-wide mapping have allowed
for further insight into the role of gene regulation by DNA
methylation.A growing body of evidence suggests that, rather
than working in isolation, DNA methylation could possibly
be intertwined with other gene silencing mechanisms. Work
specifically looking at the modulation of chromatin has
produced various theories on the functional role of CpG
islandmethylation at promotor sites in respect to gene expres-
sion. One hypothesis surrounding the role of DNA methyla-
tion is that it may modulate polycomb protein targeting [10].
Several studies gave early indications that PRC2 (polycomb
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repressor complex 2) played a key role by observing that
PRC2 components were binding to CpG islands [11–13].
Specifically the histone marker H3K27me3, a trimethylated
histone, has been used in studies as a signature of PRC2
activity and has also been identified to cause gene silencing
through several mechanisms [14]. Interestingly, a negative
correlation has been suggested to exist between DNAmethy-
lation, H3K27me3, and CpG high density regions [15, 16].
This has led to the theory that DNA methylation may
negatively regulate the targeting of polycomb proteins [10].
Data to support this is still correlative, where global levels of
hypomethylation are associatedwith increased PRC2 binding
[11, 14, 15], but further work is needed to establish the
temporal and spatial relationship between DNA methylation
and polycomb targeting and regulation of gene expression.
Though the canonical regulation of promotor sites by
methylation is an important phenomenon observed in X-
chromosome inactivation and imprinting [1, 17], the actual
role of methylation in developmental processes and embry-
onic patterning is not well understood. While hypomethy-
lated promotor sites are found to be present at important
germline specific genes during development, these genes are
also found to be methylated in somatic cells [5]. Though
studies have shown that the absence of methylation in mouse
embryo models have led to the activation of specific genes
[18, 19], it is unclear whether the methylation process itself is
directly involved in gene silencing in embryonic patterning
and highlights the complex role of methylation in devel-
opmental processes. Methylation of nonpromoter regions
appears to be largely irreversible and this epigenetic memory
and irreversibility are an important property of gene silencing
in early development to produce monoallelic expression of
specific genes [20]. In contrast to this, plasticity of methyla-
tion patterns at promotor sites has been suggested to regulate
cellular properties such as pluripotency in HSCs to prevent
uncontrolled differentiation [18, 20, 21].
The identification of areas flanking CpG islands, called
“shores” and “shelves,” adds further complexity to the regula-
tion of gene expression. Shores are identified as being 0–2 kb
away from islands, while shelves are 2–4 kb away; further-
more, “open sea” sites, which are spread throughout the
genome itself, have also been identified [22, 23]. Aberrant lev-
els of hypomethylation and hypermethylation of these shores,
shelves, and open sea sites have been associated with several
malignant processes [2]. However, the significance of such
areas and the pattern ofmethylation observed in these disease
processes at these sites is still unclear. Recent studies investi-
gating HSCs have identified hypomethylated regions referred
to as “canyons” [24].These canyons may overlap CpG islands
but are characteristically distinct from low-methylated
islands [24]. Canyons are seen to be conserved across cell
types and species. Genes associated with haematopoiesis are
reported to be enriched in canyons and are vulnerable to
methylation dysfunction observed in haematological malig-
nancy [24].
Global hypomethylation and associated overall genomic
instability in DNA elements such as exons, introns, and
transposons have been suggested to have a role in disease
processes [9, 25]. Altered levels of methylation have been
associated with instability of microsatellite repeats; dysfunc-
tion of such repeat elements is well characterized in diseases
such as Huntington’s disease and cancer [9]. In addition
to hypomethylated promotor sites being transcriptionally
active, global hypomethylation has also been associated with
the activation of new enhancer sites, similarly resulting in
gene upregulation [26].
1.3. DNA Methyltransferase (DNMT) Enzymes. DNAmethy-
lation is carried out by a family of DNA methyltransferase
enzymes, which include DNMT1, DNMT3A, and DNMT3B.
Figure 2 illustrates the structure of these genes. By contrast,
DNMT3L has no catalytic domain and predominantly func-
tions as an accessory protein to DNMT3A [29]. Studies have
suggested that DNMT3L may work to localise DNMT3A to
chromatin sites in developmental processes and is also seen
to interact with DNMT3B in vivo [29].
The methylation of existing genomic CpG islands is car-
ried out by DNMT1 (see Figure 1). Several studies have iden-
tified the importance of this enzyme. Dysfunction of DNMT1
has been shown to contribute to various different types of
malignancies such as colorectal and prostate cancer [30]. In
knockdown mice models, DNMT1(−/−) demonstrated a 90%
loss ofmethylation andwas associatedwith embryonic lethal-
ity suggesting its incompatibility with life [30, 31]. Though
viable, DNMT1(−/−) embryonic mice stem cells resulted in
loss of important cellular function such as differentiation [32].
The loss of DNMT1 and subsequent loss of genomic stability
and viability of cellular function [31] are all characteristics
noted in many malignant processes.
The methylation of de novo (new) genomic sequence
is carried out by both DNMT3A and DNMT3B (see Fig-
ure 1) [29, 33]. The knockdown of both DNMT3b(−/−) and
DNMT3a(−/−) mice embryonic stem cells are not observed
to be compatible with life due to the extensive disruption of
normal developmental process [33], confirming a crucial role
of DNMT3 enzymes in embryonic development.
1.4. TET Enzymes. While the addition ofmethyl group is car-
ried out by DNMT enzymes, the removal of themethyl group
and conversion to unmodified state occur through both the
inhibition of DNMT enzymes and also by the action of a
group of enzymes known as Ten-Eleven-Translocases (TET
1, 2, and 3). TET enzymes demethylate DNA by producing
several intermediates, 5-hydroxymethylcytosine (5hmC), 5-
formylcytosine (5fC), and 5-carboxylcytosine (5CaC) [34]. In
addition to being an intermediate, 5hmC in particular may
have other roles in development, as studies have observed the
acquisition of 5hmC by genes that are activated in neuronal
cells during both postnatal developments and also during
aging [35].
Mutations in TET enzymes can also contribute to the
development of cancer including leukaemia [36].While TET1
has previously been identified as a fusion protein in MLL
(mixed lineage leukaemia) [37], nearly 8–23% of adult AML
patients carry a mutation in TET2 [38–40]. In intermediate-
risk cytogenetic AML, TET2 mutations have been associated
with poor prognosis [41]. Mutations in TET2 may be an
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Figure 2: Structure of DNMT3A splice isoforms, DNMT3B, and DNMT3L. Shown here is the structure of the DNMT3 enzymes. The ADD
domain is related to the PHD- (plant homeodomain-) like regulator ATRX and has strong interactions with histones, which is thought
to enhance its methylation activity. Meanwhile PWWP domain (Pro-Trp-Trp-Pro) is found to interact with DNA and heterochromatin to
help carry out its function, among other proteins. The catalytic domain of the enzyme has motifs conserved across the isoforms. Motifs I
are cofactor binding while motifs VIII and IX are for DNA binding and methylation activity at motifs IV, VI, and VIII. The main difference
between the two splice isoforms of DNMT3A1 andDNMT3A2 is the extra DNA binding domain located at the amino terminal of DNMT3A1.
Other DNMT enzymes are also able to interact with DNMT3A. One common mutation site shown here is R882 residue. This is a hotspot
for mutations in haematological malignancy and preleukaemic conditions. Not depicted here are the splice isoforms for DNMT3B and the
structure of DNMT1. Adapted from Yang et al. [2].
early phenomenon as they are found in approximately 20%
of preleukaemic conditions such as MDS (myelodysplastic
syndrome) and MPN (myeloproliferative neoplasms) [42,
43].
Direct dysfunction in enzymatic activity due to mutation
in TET2 and subsequent low levels of 5hmC have been asso-
ciated with myeloid tumorigenesis [44]. However, Figueroa
et al. [45, 46] have suggested that it is the concomitant
gain of function IDH1/2 (isocitrate dehydrogenase 1 and 2)
mutations which impairs TET2 catalytic activity resulting in
tumorigenesis andTET2mutations alone do not substantially
alter 5hmC levels. In addition to this bothmurine and human
studies have shown that the loss of TET2 does not result
in leukaemic transformation but does lead to preleukaemic
states such as MDS through activation of downstream genes
associated with self-renewal and cellular growth [47]. How-
ever, mouse models in contrast to this have shown that the
loss of TET2 is sufficient for HSC self-renewal and malignant
transformation, proposing that TET2 may still play a part in
the leukaemogenic process [48].
1.5. DNMT3AStructure and Function. TheDNMT3Aprotein
is encoded on human chromosome 2p23 and is a small
protein of 130 kDwith several different domains [49]. Figure 2
shows the structure of DNMT3A; the human enzyme has
two known splice isoforms DNMT3A1 and DNMT3A2 [50].
Expression of the two splice isoforms varies in different
tissues. DNMT3A2, the shorter of the two isoforms, is
predominantly expressed in embryonic stem cell found in
the ovaries and testes [50], while DNMT3A1 is expressed
ubiquitously in all tissues at low levels [50]. As observed with
DNMT3B, transcription of DNMT3A1 occurs at two distinct
promoter regions, both of which have differing levels of CpG
content [51].The control of expression of tissue specific splice
forms of DNMT3A and the significance of the two promotor
sites remain unclear.
As Figure 2 shows DNMT3A does not work in isolation
and is seen to interact with several epigenetic modifiers
through its different domains to carry out its function.
Though it is unclear how DNMT3A is initially recruited to
the chromatin, it is able to interact with the various types
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of histones at these sites [52]. The ADD (ATRX/DNMT3-
DNMT3L) domain of DNMT3A may interact with histone
tails to guide the enzyme to the chromatin [53]. How-
ever, interactions between histones and DNMT3A may be
more complex than this. Recent data has suggested that
the ADD domain may autoinhibit its own catalytic activity
and through interaction with histones such as H3K4me0
(unmodified histone) this inhibition is released (Guo et al.,
2015). Histones such as H3K27me3 are also observed to
cover hypomethylated CpG canyons found in HSCs and are
suggested to mark gene for methylation [24]. Such canyon
regions may potentiate the interaction between DNMT3A
and histones for functional purposes as previously discussed
with respect to PRC2 gene silencing. However, as canyons are
seen to be hypomethylated it is unclear how this interaction
encompasses DNMT3A directly.
Several other epigenetic modifiers also bind DNMT3A
for functional purposes to modify gene expression. One
example of this is histone modifiers, such as H3K9 methyl-
transferase enzyme, which are observed to interact with
DNMT3A [52], though the significance in respect to methy-
lation activity is not well understood. Interactions between
DNMT3A and SUV39H1 (histone methyltransferase) have
also resulted in H3K9methylation and subsequently reduced
gene expression [54]. Another histone modifier that binds to
DNMT3A through the ADD domain is EZH2 (Enhancer of
Zeste homology 2) (see Figure 2). A catalytic component of
PRC2, EZH2 is required for DNMT3A to bind genes that are
consequently repressed byEZH2 [55]. Together these two epi-
genetic regulators may have a role in normal haematopoiesis,
as mutations in EZH2 are seen in both MDS and myeloid
malignancies [56].
Other members of DNMT family also interact with
DNMT3A (see Figure 2).Methylated regions are seen to over-
lap for DNMT3A and DNMT3B, though it is uncertain why
both enzymes are required for methylation of the same site.
Some models have suggested that DNMT3A and DNMT3B
work as a dimer to methylate certain satellite repeats [57].
The significance of this dimer structure is unclear; whether
the dimer is required to localise satellite repeats or poten-
tiate the DNMT3A methylating function still remains to be
determined. Certain tissues which lack the accessory pro-
tein DNMT3L express both DNMT3A and DNMT3B [57],
suggesting that DNMT3B may have an accessory role. When
DNMT3L is coexpressed with DNMT3A, enzymatic activity
is increased nearly threefold [58] but the mechanism of this
is not clearly characterised. DNMTL is not seen to enhance
DNMT3A binding to DNA [58] and neither does it appear to
help guide DNMT3A to unmodified chromatin [53]. Further
studies may identify the significance and relevance of this
interaction in human tissue.
2. DNMT3A and Acute Myeloid Leukaemia
2.1. AcuteMyeloid Leukaemia. AML is haematological cancer
that affects the myeloid lineage and causes clonal malignant
proliferation of white blood cells [68]. Inhibited differentia-
tion and uncontrolled proliferation lead to accumulation of
immature blood cells in the bone marrow; progression of
this leads to cytopenia, neutropenia, and thrombocytopenia.
Clinical manifestations of symptoms include fatigue, dysp-
noea, susceptibility to infections, and haemorrhage. AML
occurs predominantly in older adults, with more than half
the cases reported in patients older than 65 years. Though
rare, infrequent cases of AML in children have been reported
[68]. Prognosis for AML patients is partly dependent on
the age of patients; younger patients are reported to have
overall better 5-year survival rate than older patients [68, 69].
Meanwhile the 5-year survival rate for those aged 65 or older
is around 15–20% [68], suggesting that the mutations driving
AML in older patients have greater associated lethality
than those found in younger patients. Importantly this also
demonstrates the devastating nature of AML as a disease.
AML is a disease of genetic heterogeneity as no single
mutation is seen to drive AML yet several mutations have
been identified to contribute to leukaemogenesis. Cytoge-
netic or chromosomal abnormalities, such as translocations,
are reported in 55% of patients with AML [70]. Different
cytogenetic aberrations can infer differing levels of risk and
prognosis as is seen in Table 1 [59, 70]. However, cytogenetic
abnormalities and molecular mutations can coincide in
leukaemia patients [59].While 40–50% of AML patients have
a normal karyotype and are cytogenetically normal (CN-
AML), these patients carry various molecular mutations that
contribute to AML pathogenesis and as such are character-
ized as being intermediate-risk group [59].
Theprogression from singlemutations in several different
genes to leukaemia is a multistep process. Early simplified
models for leukaemogenesis included the two-hit hypothesis,
whereby two hits in two different mutation groups were
needed [71].These groupswere referred to asClass I andClass
II. Mutations in genes that cause uncontrolled proliferation
of cells and avoidance of apoptosis were grouped as Class I
mutations, while Class II mutations inhibited differentiation
as seen in Figure 3.
With respect to AML this theory was supported by
genomic sequencing data showing the presence of Classes
I and II mutations such as FLT3 (tyrosine kinase) and
NPM1 (nucleophosmin) in CN-AML patients with no other
identifiable chromosomal abnormalities [72]. In addition to
this, Higuchi et al. (2002) demonstrated in leukaemia mice
models that a single mutation in genes did not progress to
leukaemogenesis, and further mutations from other classes
were required [73]. This evidence, in conjunction with the
observation that no single mutation has been identified to
drive AML, supported the suggestion that more than one
mutation is required. Single mutations from Class II are,
however, observed to cause preleukaemic conditions such as
MDS [74].
However, the two-hit hypothesis is simplistic in regard
to mutational groups considered. The role of mutations in
epigenetic modifiers such as DNMT3A is excluded from
this theory, though data is increasingly proposing that these
mutations have a significant contribution to leukaemoge-
nesis. The introduction of mutations from neither Class I
nor Class II has added further complexity to understanding
haematological malignancies [27]. Figure 3 shows some of
these genes from different classes identified to date.
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Table 1: Showing the cytogenetic abnormalities that are found in AML and the current known functional consequences of these fusion
proteins. Taken and adapted from Kumar et al. (2010) and individual sources as referenced below.
Translocations Oncofusion protein Frequency in AML Consequence of translocation
t(8;21) AML1-ETO 10%
Translocation involves the AML1 (RUNX1), a DNA binding TF important
for haematopoietic differentiation and the ETO gene (a transcriptional
repressor) to give oncofusion protein. The suggested function of the
oncofusion is to exert dominant-negative effect on AML1WT to suppress
haematopoietic differentiation [59].
t(15;17) PML-RAR𝛼 10%
The PML-RAR𝛼 is expressed in haematopoietic myeloid cells and functions
as a transcriptional repressor of genes involved in apoptosis, differentiation,
and self-renewal [59].
inv(16) CBF𝛽-MYH11 5–8% CBF𝛽-MYH11 oncofusion protein is suggested to interact with AML1 torepress transcription in myeloid cells [59].
der(11q23) MLL-fusions 4%
Observed in various acute leukaemia and is associated with poor
prognosis. The oncofusion protein acts a potent oncogene. It directs the
MLL oncoprotein targets complex to DNA sites, while fusion part works as
an effector unit [59].
t(9;22) BCR-ABL1 2% Rare Philadelphia-positive AML [60].
t(6;9) DEK-CAN <1% Chimeric fusion protein encodes a mRNA involved in leukaemogenesis[61].
t(1;22) OTT-MAL <1% May regulate chromatin structure, HOX differentiation pathways, orextracellular signaling [62].
t(8;16) MOZ-CBP <1% Upregulation of HOX genes and downregulation of WT1; shares similarpathway as MLL [63].
t(7;11) NUP98-HOXA9 <1% Inhibition of HOXA9 effecting terminal differentiation [64].
inv(3) RPN1-EVI1 <1% The EVI1 fusion induces gene transcription and promotes leukaemogenesis[65].
t(16;21) FUS-ERG <1% Oncofusion protein that acts as a transcriptional repressor ofhaematopoietic specific genes [66].
2.2. Epigenetic Mutations and AML. The use of more
advanced whole genome and whole exome of sequencing
techniques has allowed for the identification of several
mutations in epigenetic regulators (see Figure 3) in AML
patients. Further research into these epigenetic modifiers has
enhanced our understanding of not only the function of
thesemodifiers in normal developmental and cellular process
but also the consequences of aberrant proteins in diseases
such as AML. Up to 70% of de novo AML patients carry a
single mutation in epigenetic modifiers such as DNMT3A
and TET2 and in some cases more than one mutation in
more than one epigenetic regulator [75]. Such mutations
have been noted in myeloid malignancies and preleukaemic
states but also in some lymphoid malignancies, notably T-
cell angioimmunoblastic lymphoma [76]. Extensive research
into these epigenetic modifiers has given insight into their
mechanisms of action in AML and here we will focus on the
current research surrounding DNMT3A mutations in AML
and the theories surrounding their mechanism of action.
2.3. AML, DNMT3A Mutations, and DNA Methylation
Patterns. Aberrant DNA methylation patterns have been
observed in several studies investigating AML pathogenesis.
Though global hypomethylation has been seen in various
genes associated with the cellular replication, hypermethy-
lation is also observed in specific CpG promoter regions
associated with tumor repressor genes involved with dif-
ferentiation and apoptosis [45, 67, 77]. In addition to this
specific signature patterns ofmethylation have been observed
across cytogenetically abnormal AML [77]. One example
is observed in PML-RAR𝛼-t(15;17) AML, where distinct
hypomethylation and hypermethylation of gene are seen,
while t(8;21) subtype AML predominant hypomethylation is
observed [67]. A summary of the alterations in methylation
pattern, compiled by Schoofs et al. (2014), can be seen in
Table 2 [67]. It is clear from the findings shown in Table 2
that much remains unclear about the aberrant methylation
patterns in relation to AML and specific mutations.
Several studies have attempted to identify the association
between specificmethylation patterns, prognosis, and clinical
outcomes [46, 78]. Figueroa et al. [45, 46] identified that
AML patients highly expressing t(8;21), inv(16), and t(15;17)
had distinct methylation patterns and therefore such groups
could be clustered together to predict clinical outcomes
[45]. Additionally, Ha´jkova´ et al. (2012) who investigated 79
AML patients and also found that high- or intermediate-risk
AML patients with higher DNA methylation were seen to
have better clinical outcomes [78]. In contrast to this, lower
levels of methylation were associated with higher relapse and
lower overall survival for AML patients [78]. Though there is
some evidence that subtypes of AML have distinct aberrant
methylation patterns this does, however, present the difficulty
of targeting such patterns with universal epigenetic changes.
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therapy in leukaemia. Adapted fromMurati et al. [27].
One frequently mutated epigenetic regulator in AML is
DNMT3A, with approximately 22% of CN-AML patients car-
rying a DNMT3A mutation [79]. Though this may suggest a
significant role for DNMT3A mutations in leukaemogenesis,
the downstream consequence of the identified mutations in
the enzyme remains largely underdetermined. While single
mutations in DNMT3A do not evolve into leukaemia or alter
levels of methylation, complete knockdown of DNMT3A in
murine models is seen to produce cellular properties such as
inhibited differentiation [80]. Challen and colleagues (2012)
have suggested this was primarily due to interruptions in
downstream regulators of DNMT3A such as RUNX1 (Runt-
related transcription factor 1), which produce malignant
properties observed with DNMT3A knockdown [80].
While it may be proposed that DNMT3A mutations
contribute to altered methylation patterns in AML, how
this occurs is not well characterized. Aberrant hypomethy-
lation patterns have been noted to occur regularly in AML,
specifically in non-CpG islands region, while hypermethy-
lation of promotor CpG islands has been highly associated
with mutated DNMT3A [81]. However, there is conflicting
evidence regarding global methylation signatures observed
in AML. Some studies have suggested no decrease in global
hypomethylation [82], while other groups have identified the
association of global hypomethylation patterns in respect to
DNMT3A mutation, particularly affecting HOX (homeobox
domain containing transcription factors) gene expression
[24, 78, 81, 83]. HOXgenes are a family of conserved homeod-
omain-containing transcription factors involved in develop-
mental processes and are seen to have an important role in
normal haematopoiesis [84, 85]. Though HOXA5, HOXA9,
and PAX appear to be overexpressed due to hypomethyla-
tion in AML [81], the significance of these genes in AML
remains to be determined.Theoverexpression ofHOXA5 and
HOXC4 genes, however, can ultimately affect differentiation
state of myeloid cells and HSCs proliferation [81]. Further
methylation studies are required to understand the impact of
DNMT3A mutations on direct modulation of such genes.
While several studies have identified hypermethylation
of CpG island promotor in AML [86, 87], less is known
about nonpromotor sites methylation. In whole-genome
studies investigating methylation patterns, predominantly
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Table 2: Effect of mutation on aberrant methylation (taken from [67]). It is clear from this table that many of the downstream consequences
in relation to development of AML are still unclear. Many of these cytogenetic mutations causing AML are rare and have only been observed
in a few patients to date.
Genetic
alteration Signature of DNA methylation patterns
Suggested mechanism of aberrant DNA methylation
induction in AML
PML-RARa
t(15;17) Accentuated hypermethylation and hypomethylation.
PML-RARa suggested to recruit DNMTs to binding site
causing DNA hypermethylation. Secondary epigenetic
dysregulation as PML-RARa binds to genomic regions
of epigenetic modifiers including DNMT3A.
AML1/ETO
t(8;21)
Accentuated hypermethylation and hypomethylation.
Though predominantly hypomethylation.
Unclear mechanism
AML1/ETO may recruit DNMT1 and HDAC1. Possibly
works through secondary DNA methylation disruption
of AML1-ETO target genes.
CBFb-MYH11
inv(16)—
t(16;16)
Predominantly hypomethylation. Unclear mechanism.
TET2 mutations Hypermethylation signature.
Mutated TET2 is impaired in its hydroxymethylation
capacity. Unclear if DNA hypermethylated genes are
direct TET2 target genes.
IDH1/2
mutations Pronounced genome wide hypermethylation signature.
Possibly via IDH (isocitrate dehydrogenase) mutations
result in DNA hypermethylation via inhibition of
𝛼-ketoglutarate dependent dioxygenases (e.g., TET2).
DNMT3A
mutations
Genome-wide DNA hypomethylation signature: studies
give mixed findings.
Mechanism of aberrant DNA methylation induction
unclear. In vitro mechanism may be through loss of
catalytic activity via R882H mutation. Unclear in vivo
mechanism.
MLL-
translocation
-(11q23)
Pronounced DNA hypomethylation signature. Unclear mechanism.
CEBP𝛼
mutations
Two patterns of hypomethylated and hypermethylated
sites depending on the detection method used. Unclear mechanism.
RUNX1
mutations
Discrete hypermethylation and hypomethylation
signature. Unclear mechanism.
NPM1
mutations
Mixed hypermethylation and hypomethylation pattern.
Strong hypomethylation in some studies. Unclear mechanism.
hypomethylation was observed in Dnmt3a(−/−) HSCs [24].
This was supported by sequential transplants of null-
DNMT3A in murine models also producing global hypo-
methylation in progeny of null cells [80]. Specifically, loss
of methylation was observed in intergenic sites in murine
Dnmt3a(−/−) HSCs [88], supporting the observations in
distant CpG shelves/shores and a small number of loci, in
other studies [79, 81]. But what remains undetermined is
the overall influence such alterations in methylation patterns
have in leukaemogenesis.
2.4. The R882 Codon Mutation in DNMT3A. Parallel DNA
sequencing techniques have identified that one of the most
commonly mutated sites in DNMT3A in AML patients is the
R882 hotspot [79, 83]. Approximately 60% of the mutations
found in DNMT3A in AML are found to occur at this
residue in the DNMT3A catalytic domain [79]. As this
mutation is highly associated with poor prognosis in adults
with AML [89], several studies have aimed to understand
the mechanism and consequences of the R882 mutation.
However, this mutation is not exclusive to just AML.Though
less frequently observed, it is nevertheless present in several
other myeloid malignancies and proliferative disorders such
as MDS [90]. As observed with AML, MDS patients with
R882 mutations are seen to have a significantly worse overall
prognosis and a more rapid progression to leukaemia than
those patients with non-R882 DNMT3A mutations [90]. In
addition to this observation, the recent identification of other
preleukaemic clones in individuals over the age of 70 has led
to the theory that the R882 mutation is one that occurs early
in the leukaemogenesis [91, 92].
Of the most common single codon mutation at the R882
residue is the arginine (R) to histidine (H)missensemutation
[79, 83]. Holz-Schietinger and colleagues (2012) suggested
that the R882H mutation formed a hypomorphic protein,
whereby the DNMT3AMUT produces a dominant-negative
effect on the enzymatic activity of DNMT3AWT [93]. Work
by Kim et al. (2013) has supported this by showing that the
coexpression in vitro of both DNMT3AWT and DNMT3MUT
in heterogeneous cells produces either a gain of function
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action or a dominant-negative effect [94]. Around 20% of
remaining function of DNMT3AWT is still maintained in the
presence of R882H mutations, potentially due to formation
of functioning DNMT3AWT dimers [93]. Disrupted dimer-
ization by DNMT3AMUT is observed to suppress half the
DNMT3AWT activity to produce approximately 2.5-fold
reduction in methylation activity [93]. This suppression of
normal activity and subsequent altered methylation could
be one possible mechanism of leukaemogenesis. While the
hypomethylation observed in murine models carrying the
R882H mutation was initially thought to produce loss-of-
function function, the successful use of the hypomethylating
agent decitabine in R882 patients contraindicates this theory
[95]. Rather than the R882H mutations causing increased
levels of global hypomethylation, an argument could bemade
for the mutation alternatively causing altered patterns in
methylation contributing to leukaemogenesis.
Recent data by Russler-Germain and colleagues (2014)
have further demonstrated a possible in vitro mechanism
of action for R882H mutation. In contradiction to pre-
vious studies, they suggested that coexpression of both
DNMT3AMUT and DNMT3AWT is required to produce the
dominant-negative effect [96]. Furthermore, rather than the
dimerisation as suggested by Holz-Schietinger et al. [93],
tetramers of DNMT3AWT are seen to form [93, 96]. It is the
loss of formation of these tetramers through the binding of
DNMT3AWT to DNMT3AMUT in a dominant-negative fash-
ion that is thought to be pathogenic as it produces inactive
intracellular complexes [96]. Interestingly, the authors also
showed that this also subsequently produced a small but
significant decrease in CpG methylation [96]. While global
hypomethylation of CpG islands and shores has been shown
in other studies to be associated with the R882H mutation
[81, 96], hypermethylation of CpG promoter regions has also
been associated with the samemutation in AML [81, 83].This
gives viability to the theory that, rather than global reduction
in methylation patterns, altered patterns are observed in
relation to R882H mutations and the extent of severity of the
mutated enzyme is ultimately dependent on the individual
cellular levels of DNMT3AMUT present.
Much still remains unclear regarding the R882H muta-
tion in respect to its activity and how this mutation works
in conjunction with other DNMT3A mutations that are
commonly observed, as is the case with many patients who
accumulate several mutations over their lifetime. Translating
such findings across to AML patients is difficult, as isolating
the function of single mutations in patient cells which have
multitude of mutations can be challenging in terms of deter-
mining functionality. Further research would endeavour to
understand the dominant-negative effect in AML patient
cells. This may also provide future therapeutic solutions that
would be beneficial to AML patients with this commonly
mutated residue. If heterozygous patients have some level
of functioning DNMT3AWT present, exploiting this action
through targeted inhibition of the R882 DNMT3AMUT could
be one avenue to pursue. However, the difficulty presented
with such therapy would be the selective targeting of mutant
DNMT3A over wildtype DNMT3A.
3. Clonal Haematopoiesis of Indeterminate
Potential and DNMT3A
A crucial step in the development of premalignant and
haematological malignancy is the clonal expansion of HSC
carrying somatic mutations. Mutated epigenetic regulators
such as DNMT3A are found in these clones of HSC and
such mutations are seen to facilitate early clonal expansion
in preleukemic conditions [90, 97].
While mutations in epigenetic regulators have been
observed in AML and preleukaemic conditions such asMDS,
recent data has shown the existence of such mutations in
elderly individuals in a novel preleukemic condition referred
to as clonal haematopoiesis of indeterminate potential.
Increasingly referred to as CHIP, this novel preleukemic con-
dition is seen to differ diagnostically from other preleukemic
conditions such as monoclonal gammopathy of unknown
significance (MGUS) and monoclonal B-cell lymphocytosis
(MBL) [28, 98]. The defining features of CHIP are illustrated
in Figure 4. Large studies using whole-exome sequencing
techniques have recently identified this phenomenon, specif-
ically characterizing the presence of somatic mutations in
three key epigenetic regulators: TET2, ASXL1, and impor-
tantly DNMT3A [91, 92]. It was concluded by both Genovese
et al. (2015) and Jaiswal et al. (2014) that somatic mutations
in these clones inferred an increased risk of haematological
malignancy [91, 92]. Of these elderly individuals who carried
mutations in DNMT3A and other epigenetic modifiers, only
4% developed lymphoid or myeloid malignancy. Though
these clones carried varied DNMT3Amutations, progression
to AML with DNMT3A was not observed in all cases.
This is the defining criterion for CHIP, whereby the clones
in CHIP carry mutations in genes notably prominent in
the development of haematological neoplasms; however, the
malignancy itself is absent [28].
While the mutations found in AML in DNMT3A, as
previously discussed, regularly occur at the R882 region of
the protein, the presence of such mutations in CHIP is
undetermined. If absent or infrequent in the landscape of
DNMT3A mutations identified in CHIP, it could suggest a
possible theory regarding the lack of progression to myeloid
malignancy. If, however, such mutations are present, this
could further support the notion of R882 mutation being a
founder mutation, one which is acquired in early leukaemo-
genesis and leads to clonal expansion.
4. Conclusion
The role of the epigenetic modifier DNMT3A in haema-
tological cancers is becoming increasingly more important.
The presence of key mutations in preleukemic stem cells in
MDS and AML, in addition to CHIP, further supports the
theory that such mutations in DNMT3A could be “founder”
mutations, especially in the case of mutations found at the
R882 codon hotspot. These mutations appear to arise in
HSCs and play a key role in the initiation of haematological
malignancy. The occurrence of such mutations has been
shown to increase with age and result in clonal expansion of
mutated cells. The significance of such mutations in CHIP
10 BioMed Research International
CHIP
(e.g., DNMT3A or TET2)
Presence of somatic
mutations associated
with haematological
neoplasia at a variant
allele frequency of 2%
Absence of definitive
morphological
evidence of a
haematological
neoplasm
Does not meet
diagnostic criteria for
PNH, MGUS, or MBL
Odds of progression to
overt neoplasia
approximately
0.5%–1% per year
Figure 4: Criteria for clonal haematopoiesis of indeterminate potential. Adapted from Steensma et al. [28]. Paroxysmal nocturnal
haemoglobinuria (PNH), monoclonal gammopathy of unknown significance (MGUS), and monoclonal B-cell lymphocytosis (MBL).
is still unclear but the relationship between CHIP and age
may suggest that such mutations are a method of adaption
to the aging bone marrow environment, potentially allowing
enhanced HSC self-renewal in older individuals.
What is clear from this review is that while mutations
in DNMT3A play a significant role in the development of
haematological disorders such as AML and MDS, under-
standing of the mechanisms and downstream consequences
of such mutations is still undetermined. Further studies may
enlighten us to the role of DNMT3A in AML and CHIP,
facilitating possible therapeutic targeting in the future.
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